Montelukast in Parkinson Disease

PHASE2/PHASE3RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

November 5, 2023

Primary Completion Date

November 20, 2024

Study Completion Date

December 20, 2025

Conditions
Parkinson Disease
Interventions
DRUG

levodopa-carbidopa

Carbidopa/levodopa, also known as levocarb and co-careldopa, is the combination of the two medications carbidopa and levodopa. It is primarily used to manage the symptoms of Parkinson's disease

DRUG

Montelukast

Montelukast and other CysLT1 antagonists are currently used as an adjuvant therapy for children and adults suffering from asthma. Other indications have been proposed and most evidence exists for the use of montelukast to treat allergic rhinitis, but its use in other inflammatory conditions, such as atherosclerosis and chronic obstructive pulmonary disease, have also been suggested.

Trial Locations (1)

35511

RECRUITING

Faculty of Medicine, Mansoura University, Al Mansurah

All Listed Sponsors
lead

Mostafa Bahaa

OTHER